For the past two months, Metastatic Trial Talk brought you the latest about cancer and COVID-19. But while the world focused on coping with the pandemic, the Food and Drug Administration kept drug approvals moving. It approved in April two new medicines for metastatic breast cancer: tucatinib (Tukysa™), for HER2-positive disease, and sacituzumab govetican (Trodelvy™), for triple-negative disease.
Below, read about the FDA approval of each new medicine, who might benefit the most, how the treatments are given and what side effects each may cause. In addition, you’ll find information on the approval of a third drug, trastuzumab deruxtican (Enhertu®), announced in late December.
Sacituzumab govetican (Trodelvy™)
- Living Beyond Breast Cancer: FDA Approves Targeted Therapy for Metastatic Triple-Negative Breast Cancer
- Metastatic Trial Search: Open Trials with Sacituzumab Govetican That Are Recruiting Metastatic Breast Cancer Patients
Trastuzumab deruxtican (Enhertu®)
- OncLive (video): HER2+ mBC: Study Design and Results of DESTINY-Breast01
- Breastcancer.org: FDA Approves Enhertu for Unresectable or Pretreated Metastatic HER2-Positive Breast Cancer
- Metastatic Trial Search: Open Trials with Trastuzumab deruxtican (DS-8201a) That Are Recruiting Metastatic Breast Cancer Patients
Relevant Topics on Metastatic Trial Talk (MTT)
Last Modified on February 25, 2021